Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) with Low-intensity Chemotherapy in Patients with Acute Lymphoblastic Leukemia (ALL)

Trial Profile

Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) with Low-intensity Chemotherapy in Patients with Acute Lymphoblastic Leukemia (ALL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Blinatumomab; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Pegfilgrastim; Rituximab; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jan 2018 Results (n=52) assessing safety and efficacy published in the Lancet Oncology
    • 13 Dec 2017 Planned number of patients changed from 206 to 256.
    • 12 Dec 2017 Results of phase II part of this study (n=70) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top